Search
Povetacicept
go.drugbank.com/drugs/DB18996InvestigationalPovetacicept is under investigation in clinical trial NCT05757570 (An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias).
Imipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigationalImipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.[L7628]
Gilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigationalGilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative...
Lysine
go.drugbank.com/drugs/DB00123ApprovedInvestigationalNutraceuticalO-Glycosylation of lysine residues in the endoplasmic reticulum or Golgi apparatus is used to mark certain proteins for secretion from the cell.
Human interferon beta
go.drugbank.com/drugs/DB14999ApprovedInvestigational[L12078] Interferon-beta has been used in the past in clinical studies with other coronaviruses due to its demonstrated activity against the virus causing Middle Eastern Respiratory Syndrome (MERS).
Branaplam
go.drugbank.com/drugs/DB14918InvestigationalBranaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).
Sodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigational[L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and
Pilocarpine
go.drugbank.com/drugs/DB01085ApprovedInvestigationalA naturally occurring alkaloid derived from the Pilocarpus plants, pilocarpine is a muscarinic acetylcholine agonist. Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors. Pilocarpine ...
Abiraterone decanoate
go.drugbank.com/drugs/DB18905InvestigationalAbiraterone decanoate is under investigation in clinical trial NCT04729114 (Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer).